



Senate

General Assembly

File No. 170

February Session, 2016

Senate Bill No. 309

Senate, March 23, 2016

The Committee on General Law reported through SEN. LEONE of the 27th Dist., Chairperson of the Committee on the part of the Senate, that the bill ought to pass.

AN ACT ESTABLISHING A TASK FORCE TO STUDY VALUE-BASED PRICING OF PRESCRIPTION DRUGS.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

- 1 Section 1. (*Effective from passage*) (a) There is established a task force
2 to study value-based pricing of prescription drugs.
- 3 (b) The task force shall consist of the following members:
- 4 (1) Two appointed by the speaker of the House of Representatives;
- 5 (2) Two appointed by the president pro tempore of the Senate;
- 6 (3) One appointed by the majority leader of the House of
7 Representatives;
- 8 (4) One appointed by the majority leader of the Senate;
- 9 (5) Two appointed by the minority leader of the House of
10 Representatives;

11 (6) Two appointed by the minority leader of the Senate;

12 (7) The Commissioner of Consumer Protection, or the
13 commissioner's designee;

14 (8) The Insurance Commissioner, or the commissioner's designee;
15 and

16 (9) The Commissioner of Public Health, or the commissioner's
17 designee.

18 (c) Any member of the task force appointed under subdivision (1),
19 (2), (3), (4), (5) or (6) of subsection (b) of this section may be a member
20 of the General Assembly.

21 (d) All appointments to the task force shall be made not later than
22 thirty days after the effective date of this section. Any vacancy shall be
23 filled by the appointing authority.

24 (e) The speaker of the House of Representatives and the president
25 pro tempore of the Senate shall select the two chairpersons of the task
26 force from among the members of the task force. Such chairpersons
27 shall schedule the first meeting of the task force, which shall be held
28 not later than sixty days after the effective date of this section.

29 (f) Not later than January 1, 2017, the task force shall submit a report
30 on its findings and recommendations to the joint standing committees
31 of the General Assembly having cognizance of matters relating to
32 consumer protection, insurance and public health, in accordance with
33 the provisions of section 11-4a of the general statutes. The task force
34 shall terminate on the date that it submits such report or January 1,
35 2017, whichever is later.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>from passage</i>	New section

GL *Joint Favorable*

The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

OFA Fiscal Note**State Impact:**

Agency Affected	Fund-Effect	FY 17 \$
Various State Agencies	GF - Potential Cost	Less than \$1,000

Note: GF=General Fund

Municipal Impact: None

Explanation

There may be a cost of less than \$1,000 in FY 17 to those agencies participating in the task force to reimburse legislators and agency staff for mileage expenses.

The Out Years

There is no ongoing fiscal impact because the task force terminates in FY 17.

OLR Bill Analysis

SB 309

AN ACT ESTABLISHING A TASK FORCE TO STUDY VALUE-BASED PRICING OF PRESCRIPTION DRUGS.

SUMMARY:

The Office of Legislative Research does not analyze Special Acts.

COMMITTEE ACTION

General Law Committee

Joint Favorable

Yea 17 Nay 0 (03/11/2016)